120 related articles for article (PubMed ID: 29247747)
1. Prognostic values of excision repair cross-complementing genes mRNA expression in ovarian cancer patients.
Zhao M; Li S; Zhou L; Shen Q; Zhu H; Zhu X
Life Sci; 2018 Feb; 194():34-39. PubMed ID: 29247747
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Value of Excision Repair Cross-Complementing mRNA Expression in Gastric Cancer.
Luo SS; Liao XW; Zhu XD
Biomed Res Int; 2018; 2018():6204684. PubMed ID: 30417012
[TBL] [Abstract][Full Text] [Related]
3. [Prediction of the efficacy of modified FOLFOX6 therapy according to the mRNA levels of thymidylate synthase (TS), excision repair cross-complementing-1 and -2( ERCC-1 and ERCC-2) and methylenetetrahydrofolate dehydrogenase( MTHFD) in the primary lesion of colorectal cancer].
Ishibashi K; Okada N; Tajima Y; Ishiguro T; Kuwabara K; Ohsawa T; Kumamoto K; Tsuji Y; Haga N; Iwama T; Ishida H; Onouchi T; Yakabi K
Gan To Kagaku Ryoho; 2011 Nov; 38(12):2220-3. PubMed ID: 22202336
[TBL] [Abstract][Full Text] [Related]
4. Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells.
Li Q; Yu JJ; Mu C; Yunmbam MK; Slavsky D; Cross CL; Bostick-Bruton F; Reed E
Anticancer Res; 2000; 20(2A):645-52. PubMed ID: 10810335
[TBL] [Abstract][Full Text] [Related]
5. Xeroderma pigmentosum complementation group C single-nucleotide polymorphisms in the nucleotide excision repair pathway correlate with prolonged progression-free survival in advanced ovarian cancer.
Fleming ND; Agadjanian H; Nassanian H; Miller CW; Orsulic S; Karlan BY; Walsh CS
Cancer; 2012 Feb; 118(3):689-97. PubMed ID: 21751198
[TBL] [Abstract][Full Text] [Related]
6. [Enhanced cisplatin cytotoxicity by RNA interfering the excision repair cross-complementing 1 gene in ovarian cancer cell lines].
Liu GY; Qu QX; Mi RR; Qi J
Zhonghua Fu Chan Ke Za Zhi; 2006 May; 41(5):339-42. PubMed ID: 16762192
[TBL] [Abstract][Full Text] [Related]
7. Phorbol ester exposure activates an AP-1-mediated increase in ERCC-1 messenger RNA expression in human ovarian tumor cells.
Li Q; Zhang L; Tsang B; Gardner K; Bostick-Bruton F; Reed E
Cell Mol Life Sci; 1999 Mar; 55(3):456-66. PubMed ID: 10228559
[TBL] [Abstract][Full Text] [Related]
8. Evidence for in the appearance of mRNAs of nucleotide excision repair genes, in human ovarian cancer tissues.
Reed E; Dabholkar M; Thornton K; Thompson C; Yu JJ; Bostick-Bruton F
Oncol Rep; 2000; 7(5):1123-8. PubMed ID: 10948350
[TBL] [Abstract][Full Text] [Related]
9. Effect of interleukin-1 alpha and tumour necrosis factor-alpha on cisplatin-induced ERCC-1 mRNA expression in a human ovarian carcinoma cell line.
Li Q; Bostick-Bruton F; Reed E
Anticancer Res; 1998; 18(4A):2283-7. PubMed ID: 9703867
[TBL] [Abstract][Full Text] [Related]
10. Clear cell tumors have higher mRNA levels of ERCC1 and XPB than other histological types of epithelial ovarian cancer.
Reed E; Yu JJ; Davies A; Gannon J; Armentrout SL
Clin Cancer Res; 2003 Nov; 9(14):5299-305. PubMed ID: 14614013
[TBL] [Abstract][Full Text] [Related]
11. MZF1 possesses a repressively regulatory function in ERCC1 expression.
Yan QW; Reed E; Zhong XS; Thornton K; Guo Y; Yu JJ
Biochem Pharmacol; 2006 Mar; 71(6):761-71. PubMed ID: 16426580
[TBL] [Abstract][Full Text] [Related]
12. [ERCC1 as a Marker of Ovarian Cancer Resistance to Platinum Drugs].
Bogush TA; Popova AS; Dudko EA; Bogush EA; Tyulyandina AS; Tyulyandin SA; Davydov MI
Antibiot Khimioter; 2015; 60(3-4):42-50. PubMed ID: 26415382
[TBL] [Abstract][Full Text] [Related]
13. TS and ERCC-1 mRNA expressions and clinical outcome in patients with metastatic colon cancer in CONFIRM-1 and -2 clinical trials.
Grimminger PP; Shi M; Barrett C; Lebwohl D; Danenberg KD; Brabender J; Vigen CL; Danenberg PV; Winder T; Lenz HJ
Pharmacogenomics J; 2012 Oct; 12(5):404-11. PubMed ID: 21788964
[TBL] [Abstract][Full Text] [Related]
14. Prognostic values of DNA mismatch repair genes in ovarian cancer patients treated with platinum-based chemotherapy.
Zhao C; Li S; Zhao M; Zhu H; Zhu X
Arch Gynecol Obstet; 2018 Jan; 297(1):153-159. PubMed ID: 29063235
[TBL] [Abstract][Full Text] [Related]
15. Cisplatin induction of ERCC-1 mRNA expression in A2780/CP70 human ovarian cancer cells.
Li Q; Gardner K; Zhang L; Tsang B; Bostick-Bruton F; Reed E
J Biol Chem; 1998 Sep; 273(36):23419-25. PubMed ID: 9722577
[TBL] [Abstract][Full Text] [Related]
16. Lactacystin enhances cisplatin sensitivity in resistant human ovarian cancer cell lines via inhibition of DNA repair and ERCC-1 expression.
Li QQ; Yunmbam MK; Zhong X; Yu JJ; Mimnaugh EG; Neckers L; Reed E
Cell Mol Biol (Noisy-le-grand); 2001; 47 Online Pub():OL61-72. PubMed ID: 11936875
[TBL] [Abstract][Full Text] [Related]
17. Distinct prognostic values of four-Notch-receptor mRNA expression in ovarian cancer.
Zhou X; Teng L; Wang M
Tumour Biol; 2016 May; 37(5):6979-85. PubMed ID: 26662955
[TBL] [Abstract][Full Text] [Related]
18. XPG mRNA expression levels modulate prognosis in resected non-small-cell lung cancer in conjunction with BRCA1 and ERCC1 expression.
Bartolucci R; Wei J; Sanchez JJ; Perez-Roca L; Chaib I; Puma F; Farabi R; Mendez P; Roila F; Okamoto T; Taron M; Rosell R
Clin Lung Cancer; 2009 Jan; 10(1):47-52. PubMed ID: 19289372
[TBL] [Abstract][Full Text] [Related]
19. [Relationship between nucleotide excision repair gene ERCC1 and resistance to cisplatin in ovarian cancer].
Liu GY; Qu QX; Mi RR; Qi J
Zhonghua Zhong Liu Za Zhi; 2008 Mar; 30(3):184-7. PubMed ID: 18756932
[TBL] [Abstract][Full Text] [Related]
20. Expression of DNA repair genes in ovarian cancer samples: biological and clinical considerations.
Ganzinelli M; Mariani P; Cattaneo D; Fossati R; Fruscio R; Corso S; Ricci F; Broggini M; Damia G
Eur J Cancer; 2011 May; 47(7):1086-94. PubMed ID: 21216588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
